-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Makes Its Debut at the 2026 South Africa Pharmaceutical Exhibition, Actively Expanding into the African Market
Category:
发布时间：2026-03-27
【概要描述】
From March 25 to 26 local time, the 2026 South African Pharmaceutical Exhibition (SAPHEX) was held at the Sandton Convention Centre in Johannesburg. The foreign trade team of Shijiazhuang Sihua Pharmaceutical Group showcased bulk specialty APIs and its competitive finished dosage forms at the exhibition, actively seeking to expand into the African pharmaceutical market.
From March 25 to 26 local time, the 2026 South African Pharmaceutical Exhibition (SAPHEX) was held at the Sandton Convention Centre in Johannesburg. The foreign trade team of Shijiazhuang Sihua Pharmaceutical Group showcased bulk specialty APIs and its competitive finished dosage forms at the exhibition, actively seeking to expand into the African pharmaceutical market.
According to reports, SAPHEX is a highly influential annual pharmaceutical industry exhibition in South Africa and across the Southern African Development Community (SADC) region. In addition to showcasing the latest pharmaceutical products and technologies, the event features high-profile conferences and forums that bring together experts from the South African Health Products Regulatory Authority (SAHPRA), the World Health Organization, and major pharmaceutical associations to discuss critical topics such as regulatory compliance, supply-chain innovation, and pan-African collaboration. As such, SAPHEX serves as one of the key gateways for entering the African pharmaceutical market.
At the exhibition, the Group’s foreign trade team leveraged the company’s flagship products and cutting-edge manufacturing processes to actively engage with both new and existing customers, with a particular focus on showcasing achievements in the development of bulk and specialty APIs. In-depth discussions were held on potential collaborations for 2026, attracting significant attention from international buyers in attendance.
In recent years, the Group has steadily intensified its international expansion, establishing itself as a high-quality supplier to numerous pharmaceutical manufacturers and food producers. Key products such as caffeine, azithromycin, theophylline, and metronidazole have seen their influence in the food additives and pharmaceutical sectors grow steadily. In 2025, the Group obtained the European Pharmacopoeia Compliance Certificate (CEP) for caffeine, enabling the product to be exported to markets across Europe, North America, South Asia, and Southeast Asia.
“Currently, the Group boasts 98 bulk and specialty active pharmaceutical ingredients, spanning multiple therapeutic areas including food additives, cardiovascular health, respiratory care, and anti-infectives, with its core competitiveness and brand influence in the international market steadily strengthening,” said the Group’s head of foreign trade. “We will continue to deepen our presence in global markets, promote the international rollout of more high-quality APIs and finished dosage forms, and inject new momentum into the smooth circulation of both domestic and international economic flows.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091